published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsJamaati, 2021 1.19 [0.38; 3.72] Rashad, 2021 2.86 [1.36; 6.01] Rashad, 2021 0.35 [0.17; 0.74] REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98] REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10] 1.05[0.54; 2.05]Jamaati, 2021, Rashad, 2021, Rashad, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020574%824seriousnot evaluable deathsdetailed resultsCAPE-COVID, 2020 0.45 [0.20; 1.02] CODEX (Tomazini), 2020 0.97 [0.72; 1.31] DEXA-COVID19, 2020 2.00 [0.21; 18.87] Edalatifard, 2020 0.29 [0.15; 0.56] Jamaati, 2021 1.19 [0.38; 3.72] Rashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 0.46 [0.24; 0.88] REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45] REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53] Steroids-SARI, 2020 0.91 [0.29; 2.86] 0.81[0.57; 1.16]CAPE-COVID, 2020, CODEX (Tomazini), 2020, DEXA-COVID19, 2020, Edalatifard, 2020, Jamaati, 2021, Rashad, 2021, Rashad, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Steroids-SARI, 20201067%1,421moderatelow deaths (time to event analysis only)detailed resultsEdalatifard, 2020 0.29 [0.15; 0.56] Rashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 0.46 [0.24; 0.88] REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45] REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53] 0.78[0.43; 1.40]Edalatifard, 2020, Rashad, 2021, Rashad, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020583%858seriousnot evaluable clinical deteriorationdetailed resultsCODEX (Tomazini), 2020 0.66 [0.43; 1.02] 0.66[0.43; 1.02]CODEX (Tomazini), 202010%299NAnot evaluable clinical improvementdetailed resultsEdalatifard, 2020 12.00 [2.39; 60.20] REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26] REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95] 1.81[0.89; 3.70]Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020372%600seriousnot evaluable clinical improvement (14-day)detailed resultsREMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03] REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64] 1.16[0.84; 1.60]REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 202020%498seriousnot evaluable death or ventilationdetailed resultsCAPE-COVID, 2020 0.71 [0.37; 1.35] REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46] REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78] 1.29[0.59; 2.80]CAPE-COVID, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020367%365moderatenot evaluable hospital dischargedetailed resultsCAPE-COVID, 2020 1.67 [0.87; 3.19] 1.67[0.87; 3.19]CAPE-COVID, 202010%149NAnot evaluable mechanical ventilationdetailed resultsCAPE-COVID, 2020 0.95 [0.44; 2.04] Jamaati, 2021 1.38 [0.45; 4.20] 1.07[0.57; 2.01]CAPE-COVID, 2020, Jamaati, 202120%199lownot evaluable radiologic improvement (14-day)detailed resultsJamaati, 2021 4.89 [1.15; 20.79] 4.89[1.15; 20.79]Jamaati, 202110%50NAnot evaluable serious adverse eventsdetailed resultsCODEX (Tomazini), 2020 0.53 [0.17; 1.62] Edalatifard, 2020 0.81 [0.11; 6.17] REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32] REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96] 1.06[0.41; 2.77]CODEX (Tomazini), 2020, Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020417%841seriousnot evaluable superinfectiondetailed resultsCAPE-COVID, 2020 0.81 [0.49; 1.34] 0.81[0.49; 1.34]CAPE-COVID, 202010%149NAnot evaluable0.510.01.0relative treatment effectwww.metaEvidence.org2024-06-05 19:22 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290